|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
03.11.26 - 12:33
|
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights (Business Wire)
|
|
|
Final NDA submission nearing completion and will be filed in the next two weeks
Launch readiness on track for expected launch in H12027, subject to FDA approval
Data from two positive Phase 3 trials reinforce COMP360's unique and highly differentiated profile of rapid onset and durability of effect with 52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year
The Phase 3 data supports the belief that COMP360 has the potential to establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a year
COMP360 expected to be a blockbuster opportunity with an estimated 4 million people in the U.S. living with TRD, a significantly underserved market where the only marketed medicine has captured...
|
|
|
|
|
27.10.26 - 11:36
|
Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026 (Business Wire)
|
|
|
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the third quarter ended September 30, 2026, and provide an update on recent developments, on November 3, 2026.
Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on November 3, 2026. A live webcast of the call will be available at the following link: https://lifescievents.com/event/csy40je/. The webcast will be archived for 30 days.
About Compass Pathways
We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-res...
|
|
|
|
|
|
|
02.10.26 - 12:36
|
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121,800 shares and restricted share units covering an aggregate of 58,000 shares. The options have an exercise price per share equal to $12.44. The equity awards to the ten newly hired non-executive employees were granted on October 1, 2026 and consisted of options to purchase an aggregate of 97,100 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 46,200 shares. These options have an exercise price per share equal to $11.95, the closing pr...
|
|
|
30.09.26 - 12:36
|
Compass Pathways Appoints Kelley Boucher as Chief People Officer (Business Wire)
|
|
|
LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer, effective today. This appointment strengthens the Compass executive team as the company continues to scale in support of its mission to bring the first classic psychedelic treatment to the field of psychiatry. In this role, Ms. Boucher will oversee the Company's people strategy, with an initial focus on guiding its planned evolution towards the launch of COMP360 psilocybin, subject to FDA approval, in the first half of 2027.
"We are thrilled to welcome Kelley to our executive team at this pivotal moment in Compass' journey. As we prepare for our NDA submission in the fourth quarter of this year, we are closer than ever to achieving our goal of introducing an entirely new treatment model in mental health care with COMP360 psilocybin,"...
|
|
|
|
|
|
|
|
|
11.09.26 - 22:15
|
Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360 (Business Wire)
|
|
|
Strata's implementation platform includes provider training, certification, site readiness, and ongoing clinical support; its founders worked with Compass on the COMP360 training program for clinicians, who supported and monitored participants in Compass' clinical trials.ATLANTA--(BUSINESS WIRE)--Strata Mental Health Solutions, the expert-led training and implementation partner preparing clinical networks to deliver psychedelic treatments, today announced it has been awarded one of the five U.S. HCP training grants awarded by Compass Pathways (Nasdaq: CMPS) to develop U.S. health care provider training programs for COMP360, Compass' investigational psilocybin treatment, if approved. Strata's founders worked with Compass on the development of the provider training program for COMP360 clinical trials. Their team is deeply experienced in training clinicians and providing direct care to patients receiving psychedelic treatments in regulated clinical settings.
Compass has reported positive results from two...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
